Viatris Inc (VTRS): Total Liabilities
$22.48B
As of 2025-12-31
$20.78B
As of 2026-06-30
-8.1%
3-year compound annual growth
-10.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $22.48B | -1.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $22.87B | -16.0% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $27.22B | -6.0% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $28.95B | -15.7% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $34.35B | -11.0% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $38.60B | +99.3% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $19.37B | n/a | 2021-03-01, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Viatris Inc (VTRS) | 2025-12-31 | $22.48B | -1.7% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $9.30B | +10.7% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $6.98B | +13.9% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $32.83B | -2.3% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $25.99B | -3.2% |
| Zoetis Inc. (ZTS) | 2025-12-31 | $12.14B | +28.2% |
| Organon & Co. (OGN) | 2025-12-31 | $12.12B | -4.1% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $3.83B | +47.9% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $6.81B | +4.5% |
Compare VTRS, REGN, VRTX, TEVA side by side · Screen every company in Pharmaceutical Preparations ↗